A strain of the common cold virus has been found to potentially target, infect and destroy cancer cells in patients with bladder cancer, a new study in the medical journal Clinical Cancer Research reports. No trace of the cancer was found in one patient following treatment with the virus.
Researchers from the University of Surrey and Royal Surrey County Hospital investigated the safety and tolerability of exposure to the oncolytic (‘cancer-killing’) virus coxsackievirus (CVA21), a naturally occurring strain of the common cold, in fifteen patients with non-muscle invasive bladder cancer (NMIBC). NMIBC is found in the tissue of the inner surface of the bladder and is the tenth most common cancer in the UK with approximately 10,000 people each year diagnosed with the illness.
Current treatments for this cancer are problematic. Transurethral resection, an invasive procedure that removes all visible lesions, has a high tumour recurrence rate ranging from 50 per cent to 70 per cent as well as a high tumour progression rate between 10 per cent and 20 per cent over a period of two to five years. Another common course of treatment, immunotherapy with Bacille Calmette-Guerin, a live bacterium used to treat bladder cancer, has been found to have serious side effects in one third of NMIBC patients while one third do not respond to the treatment at all.
During this pioneering study fifteen NMIBC patients, one week prior to pre scheduled surgery to remove their tumours, received CVA21 via a catheter in the bladder. Examination of tissue samples post-surgery discovered that the virus was highly selective, targeting only cancerous cells in the organ and leaving all other cells intact. The virus was found to have infected cancerous cells and replicated itself causing the cells to rupture and die. Urine samples taken from patients on alternate days detected ‘shedding’ from the virus indicating that once virally infected cancer cells had died, the newly replicated virus continued to attack more cancerous cells in the organ.
Typically tumours in the bladder do not have immune cells, preventing a patient’s own immune system from eliminating the cancer as it grows. Evidence suggests treatment with CVA21 inflames the tumour causing immune cells to rush into the cancer environment, targeting and killing the cancer cells. These tumours devoid of immune cells are known as ‘cold’ areas immunologically; however, treatment with the virus causes inflammation and immune cell stimulation to create ‘immunological ‘heat’. ‘Hot’ tumours in this way are more likely to be rejected by the immune system.
Following treatment with the virus cell death was identified in the majority of the patients’ tumours. In one patient no trace of the cancer was found during surgery.
Hardev Pandha, Principal Investigator of the study and Professor of Medical Oncology at the University of Surrey, said: “Non-muscle invasive bladder cancer is a highly prevalent illness that requires an intrusive and often lengthy treatment plan. Current treatment is ineffective and toxic in a proportion of patients and there is an urgent need for new therapies.
“Coxsackievirus could help revolutionise treatment for this type of cancer. Reduction of tumour burden and increased cancer cell death was observed in all patients and removed all trace of the disease in one patient following just one week of treatment, showing its potential effectiveness. Notably, no significant side effects were observed in any patient.”
Dr Nicola Annels, Research Fellow at the University of Surrey, said: “Traditionally viruses have been associated with illness however in the right situation they can improve our overall health and wellbeing by destroying cancerous cells. Oncolytic viruses such as the coxsackievirus could transform the way we treat cancer and could signal a move away from more established treatments such as chemotherapy.”
The Latest on: Bladder cancer
via Google News
The Latest on: Bladder cancer
- Bladder Cancer Detection Videoson January 24, 2021 at 4:27 pm
In this conversation with Ashish Kamat, MD, Arjun Balar, MD, MBBS, discusses testing the concept of effectively treating bladder cancer without needing chemotherapy in the non-muscle-invasive disease ...
- Study shows taking aspirin can help cancer patients increase their chance of survivalon January 20, 2021 at 9:18 am
Aspirin could improve survival rate for some cancer patients, according to a study by the National Cancer Institute. Researchers with the institute say breast cancer and bladder cancer patients could ...
- Theralase Launches Second Clinical Study Site in the US for Phase II Bladder Cancer Clinical Studyon January 20, 2021 at 4:29 am
Theralase has central IRB approval to launch a number of US clinical sites, subject to local site IRB approval. UA is the second site to receive both central and local site IRB approval. There are 4 ...
- Aspirin found to improve survival in breast and bladder cancer patientson January 18, 2021 at 7:38 pm
A new study from the US has found that taking aspirin regularly can lengthen the lifespan of certain cancer sufferers aged 65 and over.
- United States Bladder Cancer Market and Competitive Landscape Report 2021on January 18, 2021 at 3:01 am
Dublin, Jan. 18, 2021 (GLOBE NEWSWIRE) -- The "US Bladder Cancer Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering. US Bladder Cancer Market and ...
- Global Bladder Cancer Market 2020: Size, Share, Demand, Trends, Growth and 2026 Forecastson January 17, 2021 at 6:46 pm
Size, Share, Demand, Trends, Growth and 2026 Forecasts Jan 17, 2021 10:00 AM ET Bladder cancer is a tumour, which starts in the cells of the bladder. Factors such as increasing incidence of ...
- New study can help determine effectiveness of chemotherapy in patients with bladder canceron January 15, 2021 at 10:24 pm
In patients with bladder cancer, chemotherapy effectiveness is partially determined by the body's immune system response to the malignancy. This is the conclusion of research conducted by a team of ...
- Regular aspirin use can lower risk for death in bladder, breast cancerson January 15, 2021 at 1:23 pm
People who take aspirin at least three times per week are more likely to survive bladder cancer, according to an analysis published Friday by JAMA Network Open.
- 2021 Global Bladder Cancer Clinical Trial Pipeline Highlights - Early & Late Stage Trials - ResearchAndMarkets.comon January 15, 2021 at 11:46 am
The “Global Bladder Cancer Clinical Trial Pipeline Highlights - 2021” report has been added to ResearchAndMarkets.com’s offering. This report provides the most up-to-date information on key pipeline ...
- Taking aspirin three times a week boosts chances of beating breast and bladder cancer by up to a third, study findson January 15, 2021 at 8:25 am
Researchers from the National Cancer Institute in the United States have revealed that aspirin can improve survival rates for some cancers, including bladder and breast.
via Bing News